Enhanced in vitro production of amyloid-like fibrils from mutant (S20G) islet amyloid polypeptide

Islet amyloid polypeptide (IAPP, “amylin”) is the amyloid-fibril-forming polypeptide in the islets of Langerhans associated with type 2 diabetes mellitus. A missense mutation in the IAPP gene associated with early-onset type 2 diabetes has been identified in the Japanese population. This mutation results in a glycine for serine substitution at position 20 of the mature IAPP molecule. Whether or not formation of islet amyloid with resulting destruction of islet tissue is the cause of this diabetes is yet not known. The present in vitro study was performed in order to investigate any influence of the amino acid substitution on the fibril formation capacity. Synthetic full-length wild type (lAPPwt) and mutant (IAPPS20G) as well as corresponding truncated peptides (position 18-29) were dissolved in dimethylsulfoxide (DMSO) or in 10% acetic acid at a concentration of 10 mg/mL and their fibril forming capacity was checked by Congo red staining, electron microscopy, a Congo red affinity assay and Thioflavine T fluorometric assay. It was found that full-length and truncated IAPPS20G both formed more amyloid-like fibrils and did this faster compared to IAPPwt. The fibril morphology differed slightly between the preparations. Conclusion: The amino acid substitution (S20G) is situated close to the region of the IAPP molecule implicated in the IAPP fibrillogenesis. The significantly increased formation of amyloid-like fibrils by IAPPS20G is highly interesting and may be associated with an increased islet amyloid formation in vivo and of fundamental importance in the pathogenesis of this specific form of diabetes.

[1]  C. Betsholtz,et al.  Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[2]  H. Levine,et al.  Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution , 1993, Protein science : a publication of the Protein Society.

[3]  D. Raleigh,et al.  Analysis of amylin cleavage products provides new insights into the amyloidogenic region of human amylin. , 1999, Journal of molecular biology.

[4]  H. Levine.  Thioflavine T interaction with amyloid β-sheet structures , 1995 .

[5]  J. Thijssen,et al.  Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model , 1999, Diabetologia.

[6]  H. Puchtler,et al.  ON THE BINDING OF CONGO RED BY AMYLOID , 1962 .

[7]  R. Holman,et al.  Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. , 1988, Diabetes research.

[8]  P. Westermark,et al.  Altered immunoreactivity of islet amyloid polypeptide (IAPP) may reflect major modifications of the IAPP molecule in amyloidogenesis , 1997, Diabetologia.

[9]  P. Westermark,et al.  Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Betsholtz,et al.  Islet amyloid polypeptide (IAPP):cDNA cloning and identification of an amyloidogenic region associated with the species-specific occurrence of age-related diabetes mellitus. , 1989, Experimental cell research.

[11]  B. Ahrén,et al.  B cell granule peptides affect human islet amyloid polypeptide (IAPP) fibril formation in vitro. , 1997, Biochemical and biophysical research communications.

[12]  N. Eberhardt,et al.  A novel assay in vitro of human islet amyloid polypeptide amyloidogenesis and effects of insulin secretory vesicle peptides on amyloid formation. , 1998, The Biochemical journal.

[13]  D. Harrison,et al.  The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. , 1999, Diabetes.

[14]  Kenneth H. Johnson,et al.  Staining methods for identification of amyloid in tissue. , 1999, Methods in enzymology.

[15]  Maria João,et al.  Transthyretin mutations in health and disease , 1995, Human mutation.

[16]  P. Lansbury,et al.  Interspecies sequence variations affect the kinetics and thermodynamics of amyloid formation : peptide models of pancreatic amyloid , 1993 .

[17]  D. Steiner,et al.  Islet Amyloid Development in a Mouse Strain Lacking Endogenous Islet Amyloid Polypeptide (IAPP) but Expressing Human IAPP , 2000, Molecular medicine.

[18]  A. Cohen,et al.  Amyloid and amyloidosis. , 1992, Current opinion in rheumatology.

[19]  D. Steiner,et al.  Effects of beta cell granule components on human islet amyloid polypeptide fibril formation , 1996, FEBS letters.

[20]  J. Bernhagen,et al.  Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide. , 1998, European journal of biochemistry.

[21]  Bruce A. Yankner,et al.  Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus , 1994, Nature.

[22]  M. Carty,et al.  Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide. , 1998, Diabetes.

[23]  H. Makino,et al.  Islet amyloid polypeptide gene: no evidence of abnormal promoter region in thirty-five type 2 diabetic patients. , 1994, Diabetes research and clinical practice.

[24]  W. Soeller,et al.  Treatment With Growth Hormone and Dexamethasone in Mice Transgenic for Human Islet Amyloid Polypeptide Causes Islet Amyloidosis and β-Cell Dysfunction , 1996, Diabetes.

[25]  T. Sanke,et al.  Missense Mutation of Amylin Gene (S20G) in Japanese NIDDM Patients , 1996, Diabetes.

[26]  P. Westermark,et al.  The pancreatic islet cells in insular amyloidosis in human diabetic and non-diabetic adults. , 2009, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.

[27]  M. McCarthy,et al.  The islet amyloid polypeptide gene and non-insulin-dependent diabetes mellitus in south Indians. , 1992, Diabetes research and clinical practice.

[28]  Kenneth H. Johnson,et al.  Islet Amyloid Polypeptide: Synthetic Peptides for Study of the Pathogenesis of Islet Amyloid , 1991 .

[29]  A Helenius,et al.  Setting the standards: quality control in the secretory pathway. , 1999, Science.

[30]  H. Levine.  Quantification of beta-sheet amyloid fibril structures with thioflavin T. , 1999, Methods in enzymology.

[31]  D. Raleigh,et al.  Effects of sequential proline substitutions on amyloid formation by human amylin20-29. , 1999, Biochemistry.

[32]  S. Kahn,et al.  Human aging is associated with parallel reductions in insulin and amylin release. , 1998, American journal of physiology. Endocrinology and metabolism.